Navigation Links
BlueInGreen® Demonstrates Better Water Treatment Solutions
Date:8/6/2013

Fayetteville, Arkansas (PRWEB) August 06, 2013

BlueInGreen, LLC recently completed a full scale demonstration of its proprietary CDOX® technology at a 120 million gallon per day (MGD) drinking water facility in the Midwest and is currently demonstrating at a municipal water treatment plant in another major city in the Midwest. The CDOX system dissolves carbon dioxide (CO2) gas into a small quantity of the treatment plant’s water and then disperses the dissolved CO2 solution into the rest of the water for the purpose of precise pH adjustment and stabilization of municipal/industrial water and wastewater. Controlling the water’s pH is necessary in order to ensure desired chemical reactions occur to remove contaminants from the water.

Due to new regulations concerning disinfection by-products, an increasing number of facilities are adding processes that utilize CO2 for pH adjustment. In addition, many treatment facilities are concerned for the safety of their employees due to the use of mineral acids, such as sulfuric, and are looking for a safer alternative. Others are looking for ways to improve efficiency and control over their existing pH adjustment processes to save money and improve water quality.

Such is the case at the 120 MGD facility mentioned, where recarbonation has historically been achieved using CO2 gas delivered via fine bubble diffusers. BlueInGreen’s CDOX system provided tighter control over pH and reduced total CO2 usage by 40% on average while using process water as the side-stream source and utilizing flow rates five times less than other systems on the market. This operations cost savings translates to a 3 year return on investment.

The company’s patented CDOX technology is unique in the industry, in that it is highly efficient, delivering nearly 100% utilization of vaporized gas. Recent installations have shown that BlueInGreen’s CDOX process makes it possible to deliver large quantities of gas in very small quantities of water – as much as 10 times less than the competition. This smaller carrier stream translates to reduced pumping costs as well as lower capital costs since smaller diameter piping, valves, flow meters, and other required components can be used.

Whether compared with conventional gas injection diffusers or other dissolved CO2 injection systems, the CDOX stands out with accurate pH control and reduced costs.

BlueInGreen, LLC is an environmental technology company established in 2004 to develop and sell high-efficiency, dissolved gas delivery technologies for use in wastewater, drinking water, and aquatic ecosystem restoration. The Company’s high-efficiency dissolved gas delivery systems include SDOX® (Super Saturated Dissolved Oxygen) for enhancing biological treatment processes, SDOX®-CS for odor and corrosion control of gravity sewers and force mains, HyDOZ® (Hyper-concentrated Dissolved Ozone) for disinfection, and CDOX® (Carbon Dioxide) for pH adjustment, water stabilization, and remineralization. BlueInGreen is actively addressing the global clean water supply and quality crisis by providing innovative products for improving water quality at lower cost and higher efficiency. BlueInGreen® is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11000755.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
2. Marrone Bio Innovations’ Zequanox® Demonstrates Control of Zebra Mussels in Illinois Lake
3. NRL demonstrates high durability of nanotube transistors to the harsh space environment
4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
5. Hark! Group demonstrates first heralded single photon source made from silicon
6. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
7. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Entinostat Demonstrates Activity in Hodgkins Lymphoma
10. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
11. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Forensics Club, takes place February 5-6 at the University’s student center, Kehr ... activities such as workshops and competitions for ample networking, learning and collaborating ...
Breaking Biology Technology:
(Date:1/15/2016)... 15, 2016 Recent publicized breaches in cyber ... new ways to ensure data security and user authentication ... and Android that ties a user,s mobile ... into a hardware authorization token. Customer service agents who ... on their KodeKey enabled device to verify their identity. ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
(Date:1/7/2016)... LONDON , Jan. 7, 2016 ... demand for biopharmaceutical products such as biologics and ... pressure to reduce healthcare expenditure, growing demand for ... growing aging population. Biosimilars are similar versions of ... with regards to their quality, safety, and efficacy. ...
Breaking Biology News(10 mins):